Latest Breaking News On - Zhang qingyuan - Page 1 : comparemela.com

APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia Foster City, CA, Hangzhou, CH, Gaithersburg, MD, Jan 07, 2021 - (ACN Newswire) - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and GlycoMimetics (Nasdaq: GLYC), today announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of relapsed/refractory acute myeloid leukemia (AML). This Breakthrough Therapy Designation for APL-106 reinforces its potential and is an important regulatory milestone for Apollomics as we prepare to initiate our clinical development work in China for patients suffering from AML, said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. AML is an aggressive disease and relapsed/refracto

Hong kongRemy bernardaJamie lacey moreiraShari annesGuo liang yuYang xiaofengZhang sufenZhang qingyuanKelly fungWilsonw cheungPorda havas international finance communications groupAsia corporate news networkDrug administrationExchange commissionNational cancer institute surveillanceChina national medical products administration